Characteristic | Before PSM | After PSM | ||
Phase 1 (n (%)) | Phase 2 (n (%)) | Phase 1 (n (%)) | Phase 2 (n (%)) | |
(n=842) | (n=1278) | (n=770) | (n=770) | |
Age (years) | 63.0±12.2 | 63.4±12.0 | 63.0±12.3 | 63.4±12.2 |
Men | 678 (80.5) | 1048 (82.0) | 619 (80.4) | 630 (81.8) |
Women | 164 (19.5) | 230 (18.0) | 151 (19.6) | 140 (18.2) |
CCI (%) | ||||
0 | 423 (50.2) | 545 (42.6)* | 389 (50.5) | 341 (44.3) |
1 | 276 (32.8) | 433 (33.9) | 252 (32.5) | 260 (33.8) |
2 | 104 (12.3) | 190 (14.9) | 93 (12.1) | 120 (15.6) |
3 | 33 (3.9) | 64 (5.0) | 30 (3.9) | 34 (4.4) |
≥4 | 6 (0.7) | 46 (3.6)** | 6 (0.8) | 15 (1.9) |
*P<0.05; **P<0.001.
CCI, Charlson Comorbidity Index; PSM, propensity score matching.